CRSP Stock Overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CRISPR Therapeutics AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$53.73 |
| 52 Week High | US$91.10 |
| 52 Week Low | US$37.55 |
| Beta | 1.74 |
| 1 Month Change | -24.29% |
| 3 Month Change | -11.93% |
| 1 Year Change | 9.41% |
| 3 Year Change | -59.26% |
| 5 Year Change | 33.39% |
| Change since IPO | 281.33% |
Recent News & Updates
Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16
Recent updates
Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Crispr Therapeutics: Nearing Harvest Season
Sep 08Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)
Aug 25News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts
Aug 09CRISPR Therapeutics GAAP EPS of -$2.40 misses by $0.19, revenue of $0.16M misses by $2.04M
Aug 08Crispr Therapeutics' Continued Progress Warrants A Buy
Jul 25Crispr Therapeutics: Innovation Day Showcases Upside Opportunities In Short And Long Term
Jun 23Shareholder Returns
| CRSP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.3% | 1.0% | 1.2% |
| 1Y | 9.4% | 0.7% | 24.9% |
Return vs Industry: CRSP exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: CRSP underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| CRSP volatility | |
|---|---|
| CRSP Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CRSP's share price has been volatile over the past 3 months.
Volatility Over Time: CRSP's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 407 | Sam Kulkarni | www.crisprtx.com |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.
CRISPR Therapeutics AG Fundamentals Summary
| CRSP fundamental statistics | |
|---|---|
| Market cap | US$4.56b |
| Earnings (TTM) | -US$153.61m |
| Revenue (TTM) | US$371.21m |
12.3x
P/S Ratio-29.7x
P/E RatioIs CRSP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRSP income statement (TTM) | |
|---|---|
| Revenue | US$371.21m |
| Cost of Revenue | US$517.58m |
| Gross Profit | -US$146.38m |
| Other Expenses | US$7.23m |
| Earnings | -US$153.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.81 |
| Gross Margin | -39.43% |
| Net Profit Margin | -41.38% |
| Debt/Equity Ratio | 0% |
How did CRSP perform over the long term?
See historical performance and comparison